Chi-Med gains scientific advice & plans to submit MAA for surufatinib
Date: 2020-08-11   Author: Saipriya Iyer  Category: #news

Chi-Med gains scientific advice & plans to submit MAA for surufatinib

Hutchison China MediTech Ltd. (Chi-Med) has recently received scientific advice from the EMA (European Medicines Agency’s) CHMP (Committee for Medicinal Products for Human Use). This scientific advice is related to surufatinib, an angio-immuno kinase inhibitor, used for the treatment of patients suffering from advanced NET (neuroendocrine tumors).

Chi-Med, based on the advice of CHMP, has concluded that the completed non-pancreatic NET (SANET-ep) and pancreatic NET (SANET-p) studies, in addition to the available data from the surufatinib studies among the pancreatic and non-pancreatic NET patients in the U.S., could form a basis for submitting the MAA (marketing authorization application). Due to the identification of no filing issues, the company is likely to submit the MAA in 2021, following the submission of the NDA (new drug application) to the U.S. FDA (Food & Drug Administration).

Surufatinib selectively inhibits tyrosine kinase activity that is associated with FGFR (fibroblast growth factor receptor) and VEGFR (vascular endothelial growth factor receptor), which inhibit angiogenesis, & CSF-1R (colony stimulating factor-1 receptor), which regulates the tumor-associated macrophages. This promotes the immune response of the body against the tumor cells. The unique dual mechanism of action of this inhibitor is anticipated to be suitable for its combinations with other immunotherapies. This may lead to the development of synergistic anti-tumor effects.

Moreover, Chi-Med has currently retained all rights to this inhibitor across the globe.

In April 2020, surufatinib was granted the Fast Track Designations for the development of non-pancreatic and pancreatic (extra-pancreatic) NET in the United States. Additionally, in November 2019, it was granted the Orphan Designation for the treatment of pancreatic NET. The company has also entered various collaboration agreements to examine the safety, efficacy, and tolerability of surufatinib, by combining with anti-PD-1 monoclonal antibodies, including tislelizumab, Tuoyi®, and Tyvyt®. These antibodies are currently approved for use in China.

Source credit:

https://www.benzinga.com/pressreleases/20/08/g17003996/chi-med-plans-to-submit-marketing-authorization-application-for-surufatinib-following-scientific-a



About Author


Saipriya Iyer

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

More from Saipriya


Post Recommendents

Hip Osteoarthritis Pain Drug Market Growth Projection from 2021 to 2026
Author: Sachin Pashte

A collective analysis on ' Hip Osteoarthritis Pain Drug market' is covered in this new research, available at Market Study Report, LLC, that offers an exhaustive study based on current trends influencing this vertical throughout assorted g...


Spine Osteoarthritis Pain Drug Market Report, Growth Forecast, Industry statistics Till 2026
Author: Sachin Pashte

A concise assortment of data on ' Spine Osteoarthritis Pain Drug market' is covered in a newly published research added to the repository of Market Study Report, LLC. It offers an exhaustive study targeting current market trends influencin...


Osteoarthritis Pain Solution Market Emerging Trends, Strong Application Scope, Size, Status, Analysis and Forecast to 2026
Author: Sachin Pashte

A detailed research on ' Osteoarthritis Pain Solution market' recently added by Market Study Report, LLC, puts together a concise analysis of the growth factors impacting the current business scenario across assorted regions. Significant i...